Ads
related to: new cancer technology news- Dosing
Learn About Dosing
And Administration.
- Explore Real Case Studies
See How A Key Opinion Leader
Treated Their Patient.
- Dosing
Search results
Results From The WOW.Com Content Network
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story.
The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient’s cells how to combat diseases like cancer ...
Hadiyah-Nicole Green (1981-) is an American medical physicist, known for the development of a method using laser-activated nanoparticles as a potential cancer treatment. [1] [2] [3] She is one of 66 black women to earn a Ph.D. in physics in the United States between 1973 and 2012, [4] and is the second black woman and the fourth black person ever to earn a doctoral degree in physics from The ...
David B. Agus (/ ˈ eɪ ɡ ə s /) is an American physician, cancer researcher and author [1] who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering [2] and the Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. [3]
At the end of the study, the responders hadn't reached the 18-month RFS endpoint, meaning that their cancer hadn't recurred in the 18 months following treatment, while the non-responders had a median RFS of 13.4 months. The authors concluded that, given the preliminary evidence of efficacy and safety, an international phase 2 trial was imminent.